Positive News SentimentPositive NewsNASDAQ:PSTX Poseida Therapeutics (PSTX) Stock Forecast, Price & News $2.34 -0.11 (-4.49%) (As of 03:10 PM ET) Add Compare Share Share Today's Range$2.28▼$2.5250-Day Range$1.62▼$2.7952-Week Range$1.54▼$8.82Volume307,183 shsAverage Volume814,292 shsMarket Capitalization$203.39 millionP/E RatioN/ADividend YieldN/APrice Target$14.33 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainability Poseida Therapeutics MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside499.7% Upside$14.33 Price TargetShort InterestHealthy6.40% of Float Sold ShortDividend StrengthN/ASustainability-0.93Upright™ Environmental ScoreNews SentimentN/AInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($1.46) to ($1.82) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.41 out of 5 starsMedical Sector244th out of 972 stocksBiological Products, Except Diagnostic Industry35th out of 158 stocks 3.5 Analyst's Opinion Consensus RatingPoseida Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $14.33, Poseida Therapeutics has a forecasted upside of 499.7% from its current price of $2.39.Amount of Analyst CoveragePoseida Therapeutics has only been the subject of 1 research reports in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted6.40% of the float of Poseida Therapeutics has been sold short.Short Interest Ratio / Days to CoverPoseida Therapeutics has a short interest ratio ("days to cover") of 3.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Poseida Therapeutics has recently decreased by 6.08%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldPoseida Therapeutics does not currently pay a dividend.Dividend GrowthPoseida Therapeutics does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScorePoseida Therapeutics has received a 73.00% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for cancer" and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Poseida Therapeutics is -0.93. Previous Next 3.3 News and Social Media Coverage News SentimentPoseida Therapeutics has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.68 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Poseida Therapeutics this week, compared to 1 article on an average week.MarketBeat Follows3 people have added Poseida Therapeutics to their MarketBeat watchlist in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Poseida Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.10% of the stock of Poseida Therapeutics is held by insiders.Percentage Held by Institutions60.83% of the stock of Poseida Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Poseida Therapeutics are expected to decrease in the coming year, from ($1.46) to ($1.82) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Poseida Therapeutics is -9.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Poseida Therapeutics is -9.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPoseida Therapeutics has a P/B Ratio of 1.10. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Poseida Therapeutics (NASDAQ:PSTX) StockPoseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company develops P-PSMA-ALLO1, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in Phase I trial for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC). It is also developing P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; and P-MUC1C-ALLO1 that is in Phase I trial for treating a range of solid tumors, including breast, colorectal, lung, ovarian, pancreatic, and renal cancers. In addition, the company engages in the development of P-CD19CD20-ALLO1 for B cell malignancies and other autoimmune diseases; and P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for multiple myeloma. Further, it is developing P-PSMA-101, an allogeneic CAR-T product candidate for treating mCRPC. Additionally, the company engages in the development of P-OTC-101, a liver-directed gene therapy for the in vivo treatment of ornithine transcarbamylase deficiency; P-FVIII-101, a clinical stage liver-directed gene therapy for the in vivo treatment of hemophilia A; and P-PAH-101, a liver-directed gene therapy for the in vivo treatment of phenylketonuria. Poseida Therapeutics, Inc. has a research collaboration and license agreement with Takeda Pharmaceuticals USA, Inc., F. Hoffmann-La Roche Ltd, and Hoffmann-La Roche Inc. The company was incorporated in 2014 and is headquartered in San Diego, California.Read More PSTX Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PSTX Stock News HeadlinesSeptember 20, 2023 | finance.yahoo.comInstitutional investors may adopt severe steps after Poseida Therapeutics, Inc.'s (NASDAQ:PSTX) latest 13% drop adds to a year lossesAugust 10, 2023 | finance.yahoo.comNews Flash: Analysts Just Made An Upgrade To Their Poseida Therapeutics, Inc. (NASDAQ:PSTX) ForecastsSeptember 29, 2023 | Tradewins (Ad)Successful Options Trading Begins With…Options trading expert Wendy Kirkland’s free guide reveals the options trading principles that are as easy to implement as they are to learn and how using them could earn you thousands in extra income each month! August 9, 2023 | finanznachrichten.dePoseida Therapeutics, Inc.: Poseida Therapeutics Provides Financial Results for the Second Quarter of 2023August 8, 2023 | finance.yahoo.comPoseida Therapeutics, Inc. (PSTX) Reports Q2 Loss, Tops Revenue EstimatesAugust 8, 2023 | finance.yahoo.comPoseida Therapeutics Provides Financial Results for the Second Quarter of 2023August 8, 2023 | msn.comWhy Are Poseida Therapeutics Shares Moving Higher Today?August 7, 2023 | marketwatch.comPoseida Therapeutics in $50 Million Investment Deal With Astellas >PSTXSeptember 29, 2023 | Tradewins (Ad)Successful Options Trading Begins With…Options trading expert Wendy Kirkland’s free guide reveals the options trading principles that are as easy to implement as they are to learn and how using them could earn you thousands in extra income each month! August 7, 2023 | marketwatch.comPoseida Therapeutics Shares Leap on Astellas Investments >PSTXAugust 7, 2023 | finance.yahoo.comAstellas and Poseida Therapeutics Announce Strategic Investment to Support Poseida's Commitment to Redefining Cancer Cell TherapyAugust 7, 2023 | finance.yahoo.comPoseida Therapeutics Announces Strategic Investment by Astellas and Provides Business UpdateJuly 31, 2023 | finance.yahoo.comThe past three years for Poseida Therapeutics (NASDAQ:PSTX) investors has not been profitableJuly 5, 2023 | finance.yahoo.comPoseida Therapeutics Announces FDA Clearance of Investigational New Drug Application for P-CD19CD20-ALLO1, an Allogeneic Dual CAR-T Cell Therapy for B-Cell MalignanciesJune 26, 2023 | finance.yahoo.comPoseida Therapeutics to Join Russell 3000® and Russell 2000® IndexesJune 13, 2023 | markets.businessinsider.comPoseida Therapeutics (PSTX) Gets a Buy from BTIGJune 1, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Xencor (XNCR) and Poseida Therapeutics (PSTX)June 1, 2023 | finance.yahoo.comPoseida Therapeutics Announces Virtual 2023 Annual Meeting of StockholdersMay 23, 2023 | msn.comHC Wainwright & Co. Reiterates Poseida Therapeutics (PSTX) Buy RecommendationMay 23, 2023 | finance.yahoo.comPoseida Therapeutics to Present at Stifel 2023 Tailoring Genes: Genetic Medicines DayMay 22, 2023 | finance.yahoo.comPoseida Therapeutics to Present at 31st Congress of the International Society on Thrombosis and HaemostasisMay 18, 2023 | finance.yahoo.comPoseida Therapeutics Presents Encouraging Preclinical Data Across its Gene Therapy Programs at the American Society for Gene and Cell Therapy 2023 Annual MeetingMay 11, 2023 | finance.yahoo.comPoseida Therapeutics First Quarter 2023 Earnings: Revenues Beat Expectations, EPS LagsMay 10, 2023 | finance.yahoo.comWhat Makes Poseida Therapeutics, Inc. (PSTX) a New Buy StockMay 10, 2023 | finanznachrichten.dePoseida Therapeutics, Inc.: Poseida Therapeutics Provides Updates and Financial Results for the First Quarter of 2023May 9, 2023 | msn.comPoseida Therapeutics GAAP EPS of -$0.45 misses by $0.03, revenue of $10.34MMay 9, 2023 | finance.yahoo.comPoseida Therapeutics, Inc. (PSTX) Reports Q1 Loss, Tops Revenue EstimatesSee More Headlines Receive PSTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Poseida Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address PSTX Company Calendar Last Earnings8/08/2023Today9/29/2023Next Earnings (Estimated)11/09/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:PSTX CUSIPN/A CIK1661460 Webwww.poseida.com Phone858-779-3100FaxN/AEmployees348Year FoundedN/APrice Target and Rating Average Stock Price Forecast$14.33 High Stock Price Forecast$15.00 Low Stock Price Forecast$14.00 Forecasted Upside/Downside+512.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.24) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-64,000,000.00 Net Margins-18.64% Pretax Margin-18.29% Return on Equity-16.77% Return on Assets-8.80% Debt Debt-to-Equity Ratio0.43 Current Ratio4.61 Quick Ratio4.61 Sales & Book Value Annual Sales$130.49 million Price / Sales1.56 Cash FlowN/A Price / Cash FlowN/A Book Value$2.18 per share Price / Book1.07Miscellaneous Outstanding Shares86,920,000Free Float85,091,000Market Cap$203.39 million OptionableNot Optionable Beta0.05 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Mark J. Gergen J.D. (Age 60)Pres, CEO & Chairman Comp: $920.74kMr. Harry J. Leonhardt Esq. (Age 66)J.D., Gen. Counsel, Chief Compliance Officer & Corp. Sec. Comp: $630.23kMr. Brent Warner (Age 39)Pres of Gene Therapy Comp: $835.93kMs. Johanna M. Mylet CPA (Age 36)Chief Financial Officer Mr. Loren WagnerSr. VP of Global OperationsMs. Kristin MartinChief People & Admin. OfficerSarah ThailingSr. Director of Corp. Communications & IRDr. Devon J. Shedlock Ph.D.Chief Scientific Officer of Cell TherapyMs. Lisa PortaleSr. VP of Regulatory AffairsDr. Jeffrey W. Winkelman J.D.Ph.D., Sr. VP & Chief Patent CounselMore ExecutivesKey CompetitorsInnate PharmaNASDAQ:IPHAMesoblastNASDAQ:MESOFate TherapeuticsNASDAQ:FATESutro BiopharmaNASDAQ:STROVigil NeuroscienceNASDAQ:VIGLView All CompetitorsInstitutional OwnershipBarclays PLCSold 70,177 shares on 9/21/2023Ownership: 0.037%Tucker Asset Management LLCBought 11,641 shares on 9/8/2023Ownership: 0.022%California State Teachers Retirement SystemSold 18,809 shares on 8/21/2023Ownership: 0.026%Nuveen Asset Management LLCBought 365,191 shares on 8/16/2023Ownership: 0.420%Lazard Asset Management LLCBought 6,066 shares on 8/15/2023Ownership: 0.021%View All Institutional Transactions PSTX Stock - Frequently Asked Questions Should I buy or sell Poseida Therapeutics stock right now? 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Poseida Therapeutics in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" PSTX shares. View PSTX analyst ratings or view top-rated stocks. What is Poseida Therapeutics' stock price forecast for 2023? 3 equities research analysts have issued 12 month price objectives for Poseida Therapeutics' stock. Their PSTX share price forecasts range from $14.00 to $15.00. On average, they expect the company's share price to reach $14.33 in the next twelve months. This suggests a possible upside of 512.5% from the stock's current price. View analysts price targets for PSTX or view top-rated stocks among Wall Street analysts. How have PSTX shares performed in 2023? Poseida Therapeutics' stock was trading at $5.30 on January 1st, 2023. Since then, PSTX stock has decreased by 55.8% and is now trading at $2.34. View the best growth stocks for 2023 here. When is Poseida Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023. View our PSTX earnings forecast. How were Poseida Therapeutics' earnings last quarter? Poseida Therapeutics, Inc. (NASDAQ:PSTX) announced its earnings results on Tuesday, August, 8th. The company reported ($0.32) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.53) by $0.21. The firm had revenue of $20.01 million for the quarter, compared to analyst estimates of $10 million. Poseida Therapeutics had a negative trailing twelve-month return on equity of 16.77% and a negative net margin of 18.64%. What ETF holds Poseida Therapeutics' stock ? Kelly CRISPR & Gene Editing Technology ETF holds 49,027 shares of PSTX stock, representing 3.32% of its portfolio. What other stocks do shareholders of Poseida Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Poseida Therapeutics investors own include Moderna (MRNA), Advanced Micro Devices (AMD), AngloGold Ashanti (AU), Micron Technology (MU), Eaton (ETN), Corning (GLW), OPKO Health (OPK), Overstock.com (OSTK), Sorrento Therapeutics (SRNE) and SSR Mining (SSRM). When did Poseida Therapeutics IPO? (PSTX) raised $150 million in an initial public offering (IPO) on Friday, July 10th 2020. The company issued 10,000,000 shares at a price of $14.00-$16.00 per share. BofA Securities, Piper Sandler and William Blair served as the underwriters for the IPO. What is Poseida Therapeutics' stock symbol? Poseida Therapeutics trades on the NASDAQ under the ticker symbol "PSTX." How do I buy shares of Poseida Therapeutics? Shares of PSTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Poseida Therapeutics' stock price today? One share of PSTX stock can currently be purchased for approximately $2.34. How much money does Poseida Therapeutics make? Poseida Therapeutics (NASDAQ:PSTX) has a market capitalization of $203.39 million and generates $130.49 million in revenue each year. The company earns $-64,000,000.00 in net income (profit) each year or ($0.24) on an earnings per share basis. How many employees does Poseida Therapeutics have? The company employs 348 workers across the globe. How can I contact Poseida Therapeutics? Poseida Therapeutics' mailing address is 9390 TOWNE CENTRE DRIVE SUITE 200, SAN DIEGO CA, 92121. The official website for the company is www.poseida.com. The company can be reached via phone at 858-779-3100 or via email at ir@poseida.com. This page (NASDAQ:PSTX) was last updated on 9/29/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Poseida Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.